Alexandre Arcaro Selected Research

Phosphatidylinositols (Phosphatidylinositol)

1/2015	The Phosphoinositide 3-Kinase p110α Isoform Regulates Leukemia Inhibitory Factor Receptor Expression via c-Myc and miR-125b to Promote Cell Proliferation in Medulloblastoma.
1/2014	Targeting class IA PI3K isoforms selectively impairs cell growth, survival, and migration in glioblastoma.
4/2013	Involvement of autophagy in the response of tumor cells to PtdIns3K inhibitors: therapeutic implications.
1/2013	Targeting the phosphoinositide 3-kinase p110-α isoform impairs cell proliferation, survival, and tumor growth in small cell lung cancer.
1/2012	Novel agents targeting the IGF-1R/PI3K pathway impair cell proliferation and survival in subsets of medulloblastoma and neuroblastoma.
11/2011	Targeting phosphoinositide 3-kinase signalling in lung cancer.
7/2011	A sensitized RNA interference screen identifies a novel role for the PI3K p110γ isoform in medulloblastoma cell proliferation and chemoresistance.
11/2008	Targeting the PI3K p110alpha isoform inhibits medulloblastoma proliferation, chemoresistance, and migration.
2/2008	Targeting the phosphoinositide 3-kinase isoform p110delta impairs growth and survival in neuroblastoma cells.
8/2007	Targeting mTOR signaling in lung cancer.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Alexandre Arcaro Research Topics

Disease

28	Neoplasms (Cancer) 06/2022 - 06/2006
8	Small Cell Lung Carcinoma (Small Cell Lung Cancer) 08/2015 - 04/2002
8	Medulloblastoma 01/2015 - 01/2007
5	Neuroblastoma 01/2012 - 12/2006
4	Polycystic Kidney Diseases (Polycystic Kidney Disease) 01/2018 - 08/2007
4	Neoplasm Metastasis (Metastasis) 11/2011 - 06/2007
3	Lung Neoplasms (Lung Cancer) 01/2013 - 08/2007
2	Carcinoma (Carcinomatosis) 01/2013 - 11/2011
2	Brain Neoplasms (Brain Tumor) 01/2012 - 01/2010
2	Autosomal Dominant Polycystic Kidney (ADPKD) 12/2009 - 08/2007
2	Cysts 12/2009 - 08/2007
1	Fibrosis (Cirrhosis) 01/2018
1	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 01/2017
1	Leukemia 01/2017
1	Glioblastoma (Glioblastoma Multiforme) 01/2014
1	Hematologic Neoplasms (Hematological Malignancy) 01/2013
1	Breast Neoplasms (Breast Cancer) 03/2011
1	Hypertrophy 12/2009
1	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 09/2007
1	Cystic Kidney Diseases (Cystic Kidney Disease) 08/2007
1	Thrombosis (Thrombus) 01/2007
1	Rheumatoid Arthritis 01/2007
1	Hypersensitivity (Allergy) 01/2007

Drug/Important Bio-Agent (IBA)

14	Phosphatidylinositols (Phosphatidylinositol)IBA 01/2015 - 12/2006
12	Protein Isoforms (Isoforms)IBA 06/2022 - 01/2007
8	TOR Serine-Threonine KinasesIBA 01/2018 - 06/2007
6	Phosphotransferases (Kinase)IBA 01/2017 - 06/2006
5	Proteins (Proteins, Gene)FDA Link 11/2011 - 12/2006
5	Ribosomal Protein S6 Kinases (S6 Kinase)IBA 03/2011 - 12/2006
4	Insulin-Like Growth Factor I (IGF-1)IBA 01/2013 - 06/2006
3	EnzymesIBA 04/2013 - 08/2007
3	Neutralizing AntibodiesIBA 01/2013 - 06/2006
3	Pharmaceutical PreparationsIBA 01/2013 - 01/2007
3	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 01/2012 - 06/2007
3	LipidsIBA 07/2011 - 01/2007
2	Glucose (Dextrose)FDA LinkGeneric 01/2017 - 01/2013
2	IGF Type 1 Receptor (IGF 1 Receptor)IBA 01/2013 - 06/2006
2	Insulin-Like PeptidesIBA 01/2013 - 06/2006
2	Insulin (Novolin)FDA Link 01/2013 - 01/2012
2	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 11/2011 - 06/2007
2	tyrosine receptor (receptor, tyrosine)IBA 11/2011 - 08/2007
2	Cisplatin (Platino)FDA LinkGeneric 07/2011 - 12/2006
2	Biological ProductsIBA 12/2010 - 01/2007
2	QuassinsIBA 12/2010 - 01/2007
2	NBT 272IBA 12/2010 - 01/2007
2	Everolimus FDA Link 12/2009 - 02/2009
2	MTOR InhibitorsIBA 12/2009 - 08/2007
2	Sirolimus (Rapamycin)FDA Link 08/2007 - 12/2006
2	Proto-Oncogene Proteins c-akt (Protein Kinase B)IBA 08/2007 - 12/2006
2	Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor)IBA 11/2003 - 04/2002
1	dactolisibIBA 01/2018
1	GlucocorticoidsIBA 01/2017
1	HexokinaseIBA 01/2017
1	Deoxyglucose (2 Deoxy D glucose)IBA 01/2017
1	Oxygen (Dioxygen)IBA 01/2017
1	Mannose (D-Mannose)IBA 01/2017
1	DNA (Deoxyribonucleic Acid)IBA 01/2015
1	Indicators and Reagents (Reagents)IBA 01/2015
1	OSM-LIF ReceptorsIBA 01/2015
1	LigandsIBA 04/2014
1	Insulin-Like Growth Factor II (Somatomedin A)IBA 01/2013
1	Phospholipase DIBA 01/2013
1	Monoclonal AntibodiesIBA 01/2012
1	teprotumumabIBA 01/2012
1	Cadherins (E-Cadherin)IBA 11/2011
1	Small Interfering RNA (siRNA)IBA 07/2011
1	Polo-Like Kinase 1IBA 07/2011
1	Transforming Growth Factors (Transforming Growth Factor)IBA 03/2011
1	telomestatinIBA 01/2010
1	Hepatocyte Growth Factor (Growth Factor, Hepatocyte)IBA 11/2008
1	Cytotoxins (Cytolysins)IBA 08/2007
1	Extracellular Signal-Regulated MAP Kinases (Extracellular Signal Regulated Kinases)IBA 08/2007
1	TensinsIBA 08/2007
1	Phosphoric Monoester Hydrolases (Phosphatases)IBA 08/2007
1	ImmunosorbentsIBA 08/2007
1	DeoxyuridineIBA 08/2007
1	Peptides (Polypeptides)IBA 06/2007
1	Growth Factor ReceptorsIBA 05/2007
1	CaveolinsIBA 01/2007
1	Insulin ReceptorIBA 12/2006
1	Somatomedin Receptors (Somatomedin Receptor)IBA 12/2006
1	NVP-AEW541IBA 12/2006
1	Antineoplastic Agents (Antineoplastics)IBA 06/2006
1	Fibroblast Growth Factors (Fibroblast Growth Factor)IBA 11/2003
1	Etoposide (VP 16)FDA LinkGeneric 11/2003
1	Cytochromes c (Cytochrome c)IBA 11/2003
1	Stem Cell FactorIBA 10/2002

Therapy/Procedure

9	Therapeutics 08/2015 - 06/2007
4	Drug Therapy (Chemotherapy) 01/2009 - 06/2007
1	Aftercare (After-Treatment) 01/2012
1	Withholding Treatment 12/2009
1	Investigational Therapies (Experimental Therapy) 06/2006